Charles Schwab Investment Management Inc. Has $1.23 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Charles Schwab Investment Management Inc. lifted its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 2.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,356 shares of the company’s stock after purchasing an additional 3,612 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Aura Biosciences were worth $1,233,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. American Century Companies Inc. bought a new position in Aura Biosciences in the second quarter worth $119,000. SG Americas Securities LLC acquired a new position in shares of Aura Biosciences in the 3rd quarter valued at $169,000. Rhumbline Advisers lifted its holdings in shares of Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after acquiring an additional 18,011 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after acquiring an additional 8,194 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after acquiring an additional 15,000 shares during the period. 96.75% of the stock is currently owned by institutional investors.

Insider Transactions at Aura Biosciences

In other news, insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This represents a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,081 shares of company stock worth $891,353. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

AURA has been the subject of a number of analyst reports. JMP Securities raised their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Scotiabank lifted their price objective on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Finally, Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Aura Biosciences presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $8.67 on Wednesday. The business’s fifty day moving average is $9.71 and its two-hundred day moving average is $8.76. The firm has a market cap of $433.08 million, a P/E ratio of -5.01 and a beta of 0.26. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. On average, equities research analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.